Étiquette : publi

Catégories
Documents English-site Tout le CNR-MyRMA

Publications du CNR-MyRMA

Publications of the NRC

2023

Publications par thème ou par année

Classification annuelle – voir ci dessous (by date, see below)
2023

Publications 2023

Cliquer ici pour toutes les publications du CNR-MyRMA en 2023

“Clinical Implications of Molecular Drug Resistance Testing for Mycobacterium Tuberculosis: A 2023 TBnet/RESIST-TB Consensus Statement” by José Domínguez et al. The Lancet Infectious Diseases, February 28, 2023. https://doi.org/10.1016/S1473-3099(22)00875-1.

2022

Publications 2022

Cliquer ici pour toutes les publications du CNR-MyRMA en 2022 – extrait ci-dessous

“Lipophilic Quinolone Derivatives: Synthesis and in Vitro Antibacterial Evaluation” by Elodie Sadowski et al. Bioorganic & Medicinal Chemistry Letters. 55 (January 1, 2022). https://doi.org/10.1016/j.bmcl.2021.128450.

2021

Publications 2021

Cliquer ici pour toutes les publications du CNR-MyRMA en 2021

“A Comprehensive Evaluation of GeneLEAD VIII DNA Platform Combined to Deeplex Myc-TB® Assay to Detect in 8 Days Drug Resistance to 13 Antituberculous Drugs and Transmission of Mycobacterium Tuberculosis Complex Directly From Clinical Samples” by Isabelle Bonnet et al. Frontiers in Cellular and Infection Microbiology. 11 (October 29, 2021). https://doi.org/10.3389/fcimb.2021.707244.

2020

Publications 2020

Cliquer ici pour toutes les publications du CNR-MyRMA en 2020

“Rifampicin and Clarithromycin (Extended Release) versus Rifampicin and Streptomycin for Limited Buruli Ulcer Lesions: A Randomised, Open-Label, Non-Inferiority Phase 3 Trial” by Richard O Phillips et al. The Lancet. 395, no. 10232 (April 18, 2020). https://doi.org/10.1016/S0140-6736(20)30047-7.

2019

Publications 2019

Cliquer ici pour toutes les publications du CNR-MyRMA en 2019

“Overall Structures of Mycobacterium Tuberculosis DNA Gyrase Reveal the Role of a Corynebacteriales GyrB-Specific Insert in ATPase Activity” by Stéphanie Petrella et al. Structure. 27, no. 4 (avril 2019). https://doi.org/10.1016/j.str.2019.01.004.

2018

Publications 2018

Cliquer ici pour toutes les publications du CNR-MyRMA en 2018

“Antimicrobial Resistance in Leprosy: Results of the First Prospective Open Survey Conducted by a WHO Surveillance Network for the Period 2009–15” by E. Cambau et al. Clinical Microbiology and Infection. 24, no. 12 (December 1, 2018). https://doi.org/10.1016/j.cmi.2018.02.022.

2017

Publications 2017

Cliquer ici pour toutes les publications du CNR-MyRMA en 2017

“Are Moxifloxacin and Levofloxacin Equally Effective to Treat XDR Tuberculosis?” by Thomas Maitre et al. Journal of Antimicrobial Chemotherapy. 72, no. 8 (August 1, 2017). https://doi.org/10.1093/jac/dkx150.

2016

Publications 2016

Cliquer ici pour toutes les publications du CNR-MyRMA en 2016

“In Vivo Mycobacterium Tuberculosis Fluoroquinolone Resistance Emergence: A Complex Phenomenon Poorly Detected by Current Diagnostic Tests” by Christine Bernard et al. The Journal of Antimicrobial Chemotherapy, September 7, 2016. https://doi.org/10.1093/jac/dkw344.

2015

Publications 2015

Cliquer ici pour toutes les publications du CNR-MyRMA en 2015

“Compassionate Use of Bedaquiline for the Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: Interim Analysis of a French Cohort” by Lorenzo Guglielmetti et al. Clinical Infectious Diseases. 60, no. 2 (January 15, 2015). https://doi.org/10.1093/cid/ciu786.

2014

Publications 2014

Cliquer ici pour toutes les publications du CNR-MyRMA en 2014

“Comparison of a Semiautomated Commercial Repetitive-Sequence-Based PCR Method with Spoligotyping, 24-Locus Mycobacterial Interspersed Repetitive-Unit–Variable-Number Tandem-Repeat Typing, and Restriction Fragment Length Polymorphism-Based Analysis of IS6110 for Mycobacterium Tuberculosis Typing” by F. Brossier et al. Journal of Clinical Microbiology. 52, no. 11 (November 1, 2014). https://doi.org/10.1128/JCM.02226-14.

2013

Publications 2013

Cliquer ici pour toutes les publications du CNR-MyRMA en 2013

“Resistance of M. Leprae to Quinolones: A Question of Relativity?” by Nicolas Veziris et al. PLoS Negl Trop Dis. 7, no. 11 (November 14, 2013). https://doi.org/10.1371/journal.pntd.0002559.

2012

Publications 2012

Cliquer ici pour toutes les publications du CNR-MyRMA en 2012 / click here

“Extending the Definition of the GyrB Quinolone Resistance-Determining Region in Mycobacterium Tuberculosis DNA Gyrase for Assessing Fluoroquinolone Resistance in M. Tuberculosis” by Alix Pantel et al. Antimicrobial Agents and Chemotherapy. 56, no. 4 (April 2012). https://doi.org/10.1128/AAC.06272-11.

2011

Publications 2011

Cliquer ici pour toutes les publications du CNR-MyRMA en 2011 / click here

“Crystal Structure of the Pyrazinamidase of Mycobacterium Tuberculosis : Insights into Natural and Acquired Resistance to Pyrazinamide” by Stéphanie Petrella et al. PLOS ONE. 6, no. 1 (January 24, 2011). https://doi.org/10.1371/journal.pone.0015785.

2010

Publications 2010

Cliquer ici pour toutes les publications du CNR-MyRMA en 2010 / click here

“Detection by GenoType MTBDRsl Test of Complex Mechanisms of Resistance to Second-Line Drugs and Ethambutol in Multidrug-Resistant Mycobacterium Tuberculosis Complex Isolates” by Florence Brossier et al. Journal of Clinical Microbiology. 48, no. 5 (May 1, 2010). https://doi.org/10.1128/JCM.01947-09.

Catégories
Documents Tout le CNR-MyRMA

Publications – Mycobactéries atypiques

NTM – Non-tuberculous mycobacteria

Seules les publications les plus récentes sont présentées – Pour voir plus de publications aller à la page de recherche : toutes les publications
Only the most recent publications are displayed – to see more, go to the search page : all publications

Chiron, R., Hoefsloot, W., Van Ingen, J., Marchandin, H., Kremer, L., Morisse-Pradier, H., Charriot, J., Mallet, J.-P., Herrmann, J.-L., Caimmi, D., Moreau, J., Dumont, Y., Godreuil, S., Bergeron, A., Drevait, M., Bouzat-Rossigneux, E., Terrail, N., Andrejak, C., Veziris, N., Grenet, D., Coudrat, A. and Catherinot, E. (2022). Amikacin Liposomal Inhalation Suspension in the Treatment of Mycobacterium abscessus Lung Infection: A French Observational Experience. Open Forum Infect Dis 9, ofac465, http://doi.org/10.1093/ofid/ofac465.
Chaptal, M., Andrejak, C., Bonifay, T., Beillard, E., Guillot, G., Guyomard-Rabenirina, S., Demar, M., Trombert-Paolantoni, S., Jacomo, V., Mosnier, E., Veziris, N., Djossou, F., Epelboin, L. and Group, F. G. P. working (2022). Epidemiology of infection by pulmonary non-tuberculous mycobacteria in French Guiana 2008–2018. PLOS Neglected Tropical Diseases 16, e0010693, http://doi.org/10.1371/journal.pntd.0010693.
Kilinç, G., Walburg, K. V., Franken, K. L. M. C., Valkenburg, M. L., Aubry, A., Haks, M. C., Saris, A. and Ottenhoff, T. H. M. (2022). Development of Human Cell-Based In Vitro Infection Models to Determine the Intracellular Survival of Mycobacterium avium. Front Cell Infect Microbiol 12, 872361, http://doi.org/10.3389/fcimb.2022.872361.
Daniau, C., Lecorche, E., Mougari, F., Benmansour, H., Bernet, C., Blanchard, H., Robert, J., Berger-Carbonne, A. and Cambau, E. (2022). Association of Healthcare and Aesthetic Procedures with Infections Caused by Nontuberculous Mycobacteria, France, 2012‒2020. Emerg Infect Dis 28, 518–526, http://doi.org/10.3201/eid2803.211791.
Lange, C., Böttger, E. C., Cambau, E., Griffith, D. E., Guglielmetti, L., van Ingen, J., Knight, S. L., Marras, T. K., Olivier, K. N., Santin, M., Stout, J. E., Tortoli, E., Wagner, D., Winthrop, K., Daley, C. L., Lange, C., Andrejak, C., Böttger, E., Cambau, E., Griffith, D., Guglielmetti, L., van Ingen, J., Knight, S., Leitman, P., Marras, T. K., Olivier, K. N., Santin, M., Stout, J. E., Tortoli, E., Wagner, D., Wallace, R. J., Winthrop, K. and Daley, C. (2022). Consensus management recommendations for less common non-tuberculous mycobacterial pulmonary diseases. The Lancet Infectious Diseases, http://doi.org/10.1016/S1473-3099(21)00586-7.
Vongthilath-Moeung, R., Plojoux, J., Poncet, A., Renzi, G., Veziris, N., Schrenzel, J. and Janssens, J.-P. (2022). Nontuberculous Mycobacteria under Scrutiny in the Geneva Area (2015–2020). RES 101, 367–375, http://doi.org/10.1159/000520033.
Bemer, P., Peuchant, O., Guet-Revillet, H., Bador, J., Balavoine, C., Basille, D., Beltramo, G., Blanc, F.-X., Blanchard, E., Boulanger, S., Bourgoin, A., Boutoille, D., Cambau, E., Canis, F., Caparros, D., Carricajo, A., Carrière, C., Couetdic, G., Couturaud, F., Dalphin, J.-C., Degot, T., Desquiens, M., Devouassoux, G., Duez, J.-M., Dumitrescu, O., Dupuy-Grasset, M., Gaudart, A., Georges, M., Godet, C., Godreuil, S., Guillouzouic, A., Hamdad-Daoudi, F., Héry-Arnaud, G., Koebel, C., Lagrange, A., Lanotte, P., Marchand-Adam, S., Mougari, F., Murris, M., Patry, I., Pérouse de Montclos, M., Raskine, L., Risso, K., Segonds, C., Sicard, D., Terru, D., Vachée, A., Vergnon, J.-M., Martin, C., Schramm, F. and Andrejak, C. (2021). Management of patients with pulmonary mycobacteriosis in France: a multicenter retrospective cohort study. BMC Pulm Med 21, 1–9, http://doi.org/10.1186/s12890-021-01701-5.
Veziris, N., Andréjak, C., Bouée, S., Emery, C., Obradovic, M. and Chiron, R. (2021). Non-tuberculous mycobacterial pulmonary diseases in France: an 8 years nationwide study. BMC Infect Dis 21, 1–10, http://doi.org/10.1186/s12879-021-06825-x.
Lecorche, E., Daniau, C., La, K., Mougari, F., Benmansour, H., Kumanski, S., Robert, J., Fournier, S., Lebreton, G., Carbonne, A., Cambau, E. and CNR-MyRMA (2021). Mycobacterium chimaera Genomics With Regard to Epidemiological and Clinical Investigations Conducted for an Open Chest Postsurgical Mycobacterium chimaera Infection Outbreak. Open Forum Infectious Diseases 8, ofab192, http://doi.org/10.1093/ofid/ofab192.
Opota, O., Mazza-Stalder, J., Viveiros, M., Cambau, E., Santin, M. and Goletti, D. (2021). Editorial: Tuberculosis and Non-tuberculous Mycobacteria Infections: Control, Diagnosis and Treatment. Frontiers in Public Health 9, URL: https://www.frontiersin.org/article/10.3389/fpubh.2021.666187 [Accessed March 2022].
Daley, C. L., Iaccarino, J. M., Lange, C., Cambau, E., Wallace, R. J., Jr, Andrejak, C., Böttger, E. C., Brozek, J., Griffith, D. E., Guglielmetti, L., Huitt, G. A., Knight, S. L., Leitman, P., Marras, T. K., Olivier, K. N., Santin, M., Stout, J. E., Tortoli, E., van Ingen, J., Wagner, D. and Winthrop, K. L. (2020). Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline. Clinical Infectious Diseases 71, e1–e36, http://doi.org/10.1093/cid/ciaa241.
Marsollier, L., Aubry, A., Carbonnelle, E., Canaan, S., Laencina, L., Cambau, E. and Herrmann, J. (2020). Mycobactérioses cutanées dues à Mycobacterium ulcerans, Mycobacterium marinum, Mycobacterium abscessus, Mycobacterium chelonae et autres mycobactéries non tuberculeuses. EM-Consulte, http://doi.org/10.1016/S1166-8598(19)81974-9.
Jaffré, J., Aubry, A., Maitre, T., Morel, F., Brossier, F., Robert, J., Sougakoff, W., Veziris, N. and the CNR-MyRMA (Centre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux) (2020). Rational Choice of Antibiotics and Media for Mycobacterium avium Complex Drug Susceptibility Testing. Frontiers in Microbiology 11, URL: https://www.frontiersin.org/article/10.3389/fmicb.2020.00081 [Accessed March 2022].
Lecorche, E., Pean de Ponfilly, G., Mougari, F., Benmansour, H., Poisnel, E., Janvier, F. and Cambau, E. (2020). Disseminated Mycobacterium chimaera Following Open-Heart Surgery, the Heater–Cooler Unit Worldwide Outbreak: Case Report and Minireview. Frontiers in Medicine 7, URL: https://www.frontiersin.org/article/10.3389/fmed.2020.00243 [Accessed March 2022].
Daniau, C., Lecorché, E., Mougari, F. and et al. (2019). Infections invasives à Mycobacterium chimaera en chirurgie cardiaque et évaluation des pratiques autour des matériels de circulation extracorporelle. Hygienes 27, 351–359, http://doi.org/10.25329/hy_xxvii_6-1.
Rollet-Cohen, V., Roux, A.-L., Bourgeois, M. L., Sapriel, G., Bahri, M. E., Jais, J.-P., Heym, B., Mougari, F., Raskine, L., Véziris, N., Gaillard, J.-L. and Sermet-Gaudelus, I. (2019). Mycobacterium bolletii lung disease in cystic fibrosis. CHEST 0, http://doi.org/10.1016/j.chest.2019.03.019.
Dutertre, M., Delobel, P., Marchou, B., Boyer, J.-F., Mougari, F. and Martin-Blondel, G. (2019). Olecranon bursitis secondary to Mycobacterium europaeum infection in a patient receiving immunosuppressive drugs for rheumatoid arthritis. Médecine et Maladies Infectieuses 49, 358–359, http://doi.org/10.1016/j.medmal.2019.03.002.
Decalonne, M., Lecorche, E., Hau, E., Petiteau, A., Moreau, C., Milan, O., Lanotte, P., Mereghetti, L., Cambau, E. and van der Mee-Marquet, N. (2019). Cause Analysis of an Infection in Facelift Surgery Due to Mycobacterium chelonae. Frontiers in Medicine 6, URL: https://www.frontiersin.org/article/10.3389/fmed.2019.00243 [Accessed February 2022].
Griffith, D. E., Eagle, G., Thomson, R., Aksamit, T. R., Hasegawa, N., Morimoto, K., Addrizzo-Harris, D. J., O’Donnell, A. E., Marras, T. K., Flume, P. A., Loebinger, M. R., Morgan, L., Codecasa, L. R., Hill, A. T., Ruoss, S. J., Yim, J.-J., Ringshausen, F. C., Field, S. K., Philley, J. V., Wallace, R. J., van Ingen, J., Coulter, C., Nezamis, J. and Winthrop, K. L. (2018). Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT). A Prospective, Open-Label, Randomized Study. Am J Respir Crit Care Med 198, 1559–1569, http://doi.org/10.1164/rccm.201807-1318OC.
Coolen-Allou, N., Touron, T., Belmonte, O., Gazaille, V., Andre, M., Allyn, J., Picot, S., Payet, A. and Veziris, N. (2018). Clinical, Radiological, and Microbiological Characteristics of Mycobacterium simiae Infection in 97 Patients. Antimicrobial Agents and Chemotherapy 62, e00395-18, http://doi.org/10.1128/AAC.00395-18.
Lecorche, E., Haenn, S., Mougari, F., Kumanski, S., Veziris, N., Benmansour, H., Raskine, L., Moulin, L., Cambau, E., Aubry, A., Brossier, F., Chauffour, A., Jaffre, J., Jarlier, V., Robert, J. and Sougakoff, W. (2018). Comparison of methods available for identification of Mycobacterium chimaera. Clinical Microbiology and Infection 24, 409–413, http://doi.org/10.1016/j.cmi.2017.07.031.
van Ingen, J., Aksamit, T., Andrejak, C., Böttger, E. C., Cambau, E., Daley, C. L., Griffith, D. E., Guglielmetti, L., Holland, S. M., Huitt, G. A., Koh, W.-J., Lange, C., Leitman, P., Marras, T. K., Morimoto, K., Olivier, K. N., Santin, M., Stout, J. E., Thomson, R., Tortoli, E., Wallace, R. J., Winthrop, K. L. and Wagner, D. (2018). Treatment outcome definitions in nontuberculous mycobacterial pulmonary disease: an NTM-NET consensus statement. European Respiratory Journal 51, 1800170, http://doi.org/10.1183/13993003.00170-2018.
Bouchet, F., Martin, B., Aubry, A., Veziris, N., Lavigne, J.-P. and Sotto, A. (2017). Should single antibiotic therapy be avoided for nontuberculous mycobacteria? Médecine et Maladies Infectieuses, http://doi.org/10.1016/j.medmal.2017.07.004.
Leyer, C., Gregorowicz, G., Mougari, F., Raskine, L., Cambau, E. and Briel, D. de (2017). Comparison of Saramis 4.12 and IVD 3.0 Vitek MS Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass Spectrometry for Identification of Mycobacteria from Solid and Liquid Culture Media. Journal of Clinical Microbiology 55, 2045–2054, http://doi.org/10.1128/JCM.00006-17.
Mougari, F., Loiseau, J., Veziris, N., Bernard, C., Bercot, B., Sougakoff, W., Jarlier, V., Raskine, L. and Cambau, E. (2017). Evaluation of the new GenoType NTM-DR kit for the molecular detection of antimicrobial resistance in non-tuberculous mycobacteria. J Antimicrob Chemother 72, 1669–1677, http://doi.org/10.1093/jac/dkx021.
Delafont, V., Samba-Louaka, A., Cambau, E., Bouchon, D., Moulin, L. and Héchard, Y. (2017). Mycobacterium llatzerense, a waterborne Mycobacterium, that resists phagocytosis by Acanthamoeba castellanii. Scientific Reports 7, 46270, http://doi.org/10.1038/srep46270.
Aubry, A., Mougari, F., Reibel, F. and Cambau, E. (2017). Mycobacterium marinum. Microbiology Spectrum 5, http://doi.org/10.1128/microbiolspec.TNMI7-0038-2016.
Mougari, F., Bouziane, F., Crockett, F., Nessar, R., Chau, F., Veziris, N., Sapriel, G., Raskine, L. and Cambau, E. (2017). Selection of Resistance to Clarithromycin in Mycobacterium abscessus Subspecies. Antimicrob Agents Chemother 61, e00943-16, http://doi.org/10.1128/AAC.00943-16.
Mougari, F., Guglielmetti, L., Raskine, L., Sermet-Gaudelus, I., Veziris, N. and Cambau, E. (2016). Infections caused by Mycobacterium abscessus: epidemiology, diagnostic tools and treatment. Expert Review of Anti-infective Therapy 14, 1139–1154, http://doi.org/10.1080/14787210.2016.1238304.
Mougari, F., Amarsy, R., Veziris, N., Bastian, S., Brossier, F., Berçot, B., Raskine, L. and Cambau, E. (2016). Standardized interpretation of antibiotic susceptibility testing and resistance genotyping for Mycobacterium abscessus with regard to subspecies and erm41 sequevar. J Antimicrob Chemother 71, 2208–2212, http://doi.org/10.1093/jac/dkw130.
Parize, P., Hamelin, A., Veziris, N., Morand, P. C., Guillemain, R., Lortholary, O. and Dupin, N. (2016). Induction therapy with linezolid/clarithromycin combination for Mycobacterium chelonae skin infections in immunocompromised hosts. Journal of the European Academy of Dermatology and Venereology 30, 101–105, http://doi.org/10.1111/jdv.12965.
Chazel, M., Marchandin, H., Keck, N., Terru, D., Carrière, C., Ponsoda, M., Jacomo, V., Panteix, G., Bouzinbi, N., Bañuls, A.-L., Choisy, M., Solassol, J., Aubry, A. and Godreuil, S. (2016). Evaluation of the SLOMYCO Sensititre® panel for testing the antimicrobial susceptibility of Mycobacterium marinum isolates. Annals of Clinical Microbiology and Antimicrobials 15, 30, http://doi.org/10.1186/s12941-016-0145-1.
Renvoisé, A., Brossier, F., Galati, E., Veziris, N., Sougakoff, W., Aubry, A., Robert, J., Cambau, E., Jarlier, V. and Bernard, C. (2015). Assessing Primary and Secondary Resistance to Clarithromycin and Amikacin in Infections Due to Mycobacterium avium Complex. Antimicrobial Agents and Chemotherapy 59, 7153–7155, http://doi.org/10.1128/AAC.01027-15.
Guglielmetti, L., Mougari, F., Lopes, A., Raskine, L. and Cambau, E. (2015). Human infections due to nontuberculous mycobacteria: the infectious diseases and clinical microbiology specialists’ point of view. Future Microbiology 10, 1467–1483, http://doi.org/10.2217/fmb.15.64.
Coolen, N., Morand, P., Martin, C., Hubert, D., Kanaan, R., Chapron, J., Honoré, I., Dusser, D., Audureau, E., Veziris, N. and Burgel, P.-R. (2015). Reduced risk of nontuberculous mycobacteria in cystic fibrosis adults receiving long-term azithromycin. Journal of Cystic Fibrosis 14, 594–599, http://doi.org/10.1016/j.jcf.2015.02.006.
Roux, A.-L., Catherinot, E., Soismier, N., Heym, B., Bellis, G., Lemonnier, L., Chiron, R., Fauroux, B., Le Bourgeois, M., Munck, A., Pin, I., Sermet, I., Gutierrez, C., Veziris, N., Jarlier, V., Cambau, E., Herrmann, J.-L., Guillemot, D. and Gaillard, J.-L. (2015). Comparing Mycobacterium massiliense and Mycobacterium abscessus lung infections in cystic fibrosis patients. Journal of Cystic Fibrosis 14, 63–69, http://doi.org/10.1016/j.jcf.2014.07.004.
Renvoise, A., Bernard, C., Veziris, N., Galati, E., Jarlier, V. and Robert, J. (2014). Significant Difference in Drug Susceptibility Distribution between Mycobacterium avium and Mycobacterium intracellulare. Journal of Clinical Microbiology 52, 4439–4440, http://doi.org/10.1128/JCM.02127-14.
Renvoise, A. and Bernard, C. (2014). Traitement des infections à Mycobacterium avium complex. J Antiinf 16, 199–206, http://doi.org/10.1016/j.antinf.2014.10.003.
Delafont, V., Mougaris, F., Cambau, E., Joyeux, michel, Bouchon, D., Hechard, Y. and Moulin, L. (2014). First evidence of amoebae – mycobacteria association in drinking water network. Environ Sci Technol, http://doi.org/10.1021/es5036255.
Fangous, M.-S., Mougari, F., Gouriou, S., Calvez, E., Raskine, L., Cambau, E., Payan, C. and Héry-Arnaud, G. (2014). Classification Algorithm for Subspecies Identification within the Mycobacterium abscessus Species, Based on Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass Spectrometry. J Clin Microbiol 52, 3362–3369, http://doi.org/10.1128/JCM.00788-14.
Mougari, F., Raskine, L., Ferroni, A., Marcon, E., Sermet-Gaudelus, I., Veziris, N., Heym, B., Gaillard, J.-L., Nassif, X. and Cambau, E. (2014). Clonal Relationship and Differentiation among Mycobacterium abscessus Isolates as Determined Using the Semiautomated Repetitive Extragenic Palindromic Sequence PCR-Based DiversiLab System. J Clin Microbiol 52, 1969–1977, http://doi.org/10.1128/JCM.03600-13.
Lerat, I., Cambau, E., Bettoni, R. R. dit, Gaillard, J.-L., Jarlier, V., Truffot, C. and Veziris, N. (2014). In Vivo Evaluation of Antibiotic Activity Against Mycobacterium abscessus. J Infect Dis 209, 905–912, http://doi.org/10.1093/infdis/jit614.
Macheras, E., Konjek, J., Roux, A.-L., Thiberge, J.-M., Bastian, S., Leão, S. C., Palaci, M., Sivadon-Tardy, V., Gutierrez, C., Richter, E., Rüsch-Gerdes, S., Pfyffer, G. E., Bodmer, T., Jarlier, V., Cambau, E., Brisse, S., Caro, V., Rastogi, N., Gaillard, J.-L. and Heym, B. (2014). Multilocus sequence typing scheme for the Mycobacterium abscessus complex. Research in Microbiology, http://doi.org/10.1016/j.resmic.2013.12.003.
Radomski, N., Roguet, A., Lucas, F. S., Veyrier, F. J., Cambau, E., Accrombessi, H., Moilleron, R., Behr, M. A. and Moulin, L. (2013). atpE gene as a new useful specific molecular target to quantify Mycobacterium in environmental samples. BMC Microbiology 13, 277, http://doi.org/10.1186/1471-2180-13-277.
Veziris, N., Chauffour, A., Escolano, S., Henquet, S., Matsuoka, M., Jarlier, V. and Aubry, A. (2013). Resistance of M. leprae to Quinolones: A Question of Relativity? PLoS Negl Trop Dis 7, e2559, http://doi.org/10.1371/journal.pntd.0002559.
Pang, S., Renvoisé, A., Perret, C., Guinier, M., Chelghoum, N., Brossier, F., Capton, E., Jarlier, V. and Sougakoff, W. (2013). Whole-Genome Sequence of Mycobacterium abscessus Clinical Strain V06705. Genome Announc 1, e00690-13, http://doi.org/10.1128/genomeA.00690-13.
Gomez, C., Ponien, P., Serradji, N., Lamouri, A., Pantel, A., Capton, E., Jarlier, V., Anquetin, G. and Aubry, A. (2013). Synthesis of gatifloxacin derivatives and their biological activities against Mycobacterium leprae and Mycobacterium tuberculosis. Bioorganic & Medicinal Chemistry 21, 948–956, http://doi.org/10.1016/j.bmc.2012.12.011.
Grammatico-Guillon, L., Lanotte, P., Bastides, F., Veziris, N., Bernard, L. and Rosset, P. (2013). Voluminous pseudotumor due to Mycobacterium malmoense. Presse Med 42, 227–230, http://doi.org/10.1016/j.lpm.2012.02.042.
Mechaï, F., Veziris, N., Aoun, O., Bille, E., Lecuit, M., Brossier, F., Viard, J. P. and Lortholary, O. (2013). In vivo selection of a multidrug-resistant Mycobacterium avium isolate in a patient with AIDS. Int J Tuberc Lung Dis 17, 141–142, http://doi.org/10.5588/ijtld.12.0778.
Mougari, F., Guglielmetti, L., Lopes, A., Raskine, L. and Cambau, E. (2013). Mycobactérioses non tuberculeuses hors mycobactérioses cutanées. In: Revue Encyclopédie Médico Chirurgicale,.
Lhuillier, E., Brugière, O., Veziris, N., Danel, C., Mourvilliers, B., Mal, H., Dauriat, G. and Ruimy, R. (2012). Relapsing Mycobacterium genavense infection as a cause of late death in a lung transplant recipient: case report and review of the literature. Exp Clin Transplant 10, 618–620, http://doi.org/10.6002/ect.2012.0052.
Dutilh, J., Caron, F., Bourgoin, A., Veziris, N. and Meurice, J.-C. (2012). Un cas atypique de mycobactérie. Revue des Maladies Respiratoires 29, 1182, http://doi.org/10.1016/j.rmr.2012.10.014.
Cosson, M.-A., Bertrand, J.-B., Martin, C., Veziris, N., Picard, C., Goulvestre, C., Coignard, S., Benoit, J.-P., Silvera, S., Moro, M.-R., Poyart, C. and Morand, P. C. (2012). Temporal interferon-gamma release response to Mycobacterium kansasii infection in an anorexia nervosa patient. J Med Microbiol 61, 1617–1620, http://doi.org/10.1099/jmm.0.042739-0.
Legout, L., Ettahar, N., Massongo, M., Veziris, N., Ajana, F., Beltrand, E. and Senneville, E. (2012). Osteomyelitis of the wrist caused by Mycobacterium arupense in an immunocompetent patient: a unique case. Int J Infect Dis 16, e761-762, http://doi.org/10.1016/j.ijid.2012.05.007.
Cambau, E., Chauffour-Nevejans, A., Tejmar-Kolar, L., Matsuoka, M. and Jarlier, V. (2012). Detection of Antibiotic Resistance in Leprosy Using GenoType LepraeDR, a Novel Ready-To-Use Molecular Test. PLoS Negl Trop Dis 6, e1739, http://doi.org/10.1371/journal.pntd.0001739.
Nessar, R., Cambau, E., Reyrat, J. M., Murray, A. and Gicquel, B. (2012). Mycobacterium abscessus: a new antibiotic nightmare. J Antimicrob Chemother 67, 810–818, http://doi.org/10.1093/jac/dkr578.
Andréjak, C., Veziris, N., Lescure, X., Cadranel, J. and Jounieaux, V. (2012). Essai CaMoMy : évaluation de la capacité de deux schémas thérapeutiques (Clarithromycine ou Moxifloxacine) à négativer les cultures à six mois de malades porteurs d’une infection pulmonaire à Mycobacterium xenopi. PHRC national 2010. Revue des Maladies Respiratoires 29, Supplement 1, A25, http://doi.org/10.1016/j.rmr.2011.10.030.
Bussone, G., Brossier, F., Roudiere, L., Bille, E., Sekkal, N., Charlier, C., Gilquin, J., Lanternier, F., Lecuit, M., Lortholary, O. and Catherinot, E. (2012). Recurrent Mycobacterium avium infection after seven years of latency in a HIV-infected patient receiving efficient antiretroviral therapy. Journal of Infection 64, 613–617, http://doi.org/10.1016/j.jinf.2011.12.020.
Prevotat, A., Bonne, S., Veziris, N., Senneville, E., Yazdanpanah, Y. and Legout, L. (2011). [Mycobacterium abscessus pulmonary infection treated with tigecyclin-amikacin and cefoxitin in a diabetic patient]. Med Mal Infect 41, 446–448, http://doi.org/10.1016/j.medmal.2011.02.011.
Radomski, N., Betelli, L., Moilleron, R., Haenn, S., Moulin, L., Cambau, E., Rocher, V., Gonçalves, A. and Lucas, F. S. (2011). Mycobacterium Behavior in Wastewater Treatment Plant, A Bacterial Model Distinct From Escherichia coli and Enterococci. Environ Sci Technol 45, 5380–5386, http://doi.org/10.1021/es104084c.
Macheras, E., Roux, A.-L., Bastian, S., Leão, S. C., Palaci, M., Sivadon-Tardy, V., Gutierrez, C., Richter, E., Rüsch-Gerdes, S., Pfyffer, G., Bodmer, T., Cambau, E., Gaillard, J.-L. and Heym, B. (2011). Multilocus Sequence Analysis and rpoB Sequencing of Mycobacterium abscessus (Sensu Lato) Strains. J Clin Microbiol 49, 491–499, http://doi.org/10.1128/JCM.01274-10.
Bastian, S., Veziris, N., Roux, A.-L., Brossier, F., Gaillard, J.-L., Jarlier, V. and Cambau, E. (2011). Assessment of Clarithromycin Susceptibility in Strains Belonging to the Mycobacterium abscessus Group by erm(41) and rrl Sequencing. Antimicrob Agents Chemother 55, 775–781, http://doi.org/10.1128/AAC.00861-10.
Cribier, B., Aubry, A., Caumes, E., Cambau, E., Jarlier, V. and Chosidow, O. (2011). [Histopathological study of Mycobacterium marinum infection]. Ann Dermatol Venereol 138, 17–22, http://doi.org/10.1016/j.annder.2010.10.025.
Ali, M. A., Bastian, S., Ismail, R., Choon, T. S., Ali, S., Aubry, A., Pandian, S., Saraswat, P., Singh, A. and Gaur, R. (2011). Discovery of novel methanone derivatives acting as antimycobacterial agents. Journal of Enzyme Inhibition and Medicinal Chemistry 26, 890–894, http://doi.org/10.3109/14756366.2011.559945.
Couderc, C., Carbonne, A., Thiolet, J. M., Brossier, F., Savey, A., Bernet, C., Ortmans, C., Lecadet-Morin, C., Coudière, I., Aggoune, M., Astagneau, P., Coignard, B. and Cambau, E. (2011). Infections à mycobactéries atypiques liées à des soins esthétiques en France, 2001–2010. Médecine et Maladies Infectieuses 41, 379–383, http://doi.org/10.1016/j.medmal.2011.02.007.
Lerat, I., Truffot, C. and Veziris, N. (2011). Infections à Mycobacterium abscessus : épidémiologie, aspects cliniques et traitement. Journal des Anti-infectieux 13, 49–55.
Radomski, N., Cambau, E., Moulin, L., Haenn, S., Moilleron, R. and Lucas, F. S. (2010). Comparison of Culture Methods for Isolation of Nontuberculous Mycobacteria from Surface Waters. Appl Environ Microbiol 76, 3514–3520, http://doi.org/10.1128/AEM.02659-09.
Bastian, S., Brossier, F., Wichlacz, C., Jarlier, V. and Veziris, N. (2010). Daptomycin is not active against rapidly growing mycobacteria. J Med Microbiol 59, 135–136, http://doi.org/10.1099/jmm.0.014274-0.
Marsollier, L., Aubry, A., Carbonnelle, E., Canaan, S., Cambau, E. and Herrmann, J.-L. (2010). Les Mycobactérioses cutanées dues à Mycobacterium ulcerans, Mycobacterium marinum, Mycobacterium abscessus, Mycobacterium chelonae et autres mycobactéries non tuberculeuses, L’Encyclopédie Médico-chirurgicale.
Cambau, E. and Aubry, A. (2010). Mycobacterium marinum. In: Tuberculosis, McGraw-Hill Professional Medical Publishing Division.
Carbonne, A., Brossier, F., Arnaud, I., Bougmiza, I., Caumes, E., Meningaud, J.-P., Dubrou, S., Jarlier, V., Cambau, E. and Astagneau, P. (2009). Outbreak of Nontuberculous Mycobacterial Subcutaneous Infections Related to Multiple Mesotherapy Injections. J Clin Microbiol 47, 1961–1964, http://doi.org/10.1128/JCM.00196-09.
Veziris, N., Aubry, A., Robert, J., Cambau, E., Jarlier, V. and Truffot-Pernot, C. (2009). Mycobacteria. In: Antibiogram, Eska and ASM editors.
Régnier, S., Martinez, V., Veziris, N., Bonvallot, T., Meningaud, J.-P. and Caumes, E. (2008). [Treatment of cutaneous infections due to Mycobacterium fortuitum: two cases]. Ann Dermatol Venereol 135, 591–595, http://doi.org/10.1016/j.annder.2008.03.029.

Catégories
Documents Tout le CNR-MyRMA

Publications – Lèpre

Jaume, L., Hau, E., Monsel, G., Mahé, A., Bertolotti, A., Petit, A., Le, B., Chauveau, M., Duhamel, E., Maisonobe, T., Bagot, M., Bouaziz, J.-D., Mougari, F., Cambau, E., Jachiet, M. and Groupe d’infectiologie en dermatologie et des infections sexuellement transmissibles (GrIDIST) (2023). Methotrexate as a corticosteroid-sparing agent in leprosy reactions: A French multicenter retrospective study Ed. Poonawala, H. PLoS Negl Trop Dis 17, e0011238, http://doi.org/10.1371/journal.pntd.0011238.
Jouet, A., Braet, S. M., Gaudin, C., Bisch, G., Vasconcellos, S., Epaminondas Nicacio De Oliveira Do Livramento, R. E., Prado Palacios, Y. Y., Fontes, A. B., Lucena, N., Rosa, P., Moraes, M., La, K., Badalato, N., Lenoir, E., Ferré, A., Clément, M., Hasker, E., Grillone, S. H., Abdou, W., Said, A., Assoumani, Y., Attoumani, N., Laurent, Y., Cambau, E., De Jong, B. C., Suffys, P. N. and Supply, P. (2023). Hi-plex deep amplicon sequencing for identification, high-resolution genotyping and multidrug resistance prediction of Mycobacterium leprae directly from patient biopsies by using Deeplex Myc-Lep. eBioMedicine 93, 104649, http://doi.org/10.1016/j.ebiom.2023.104649.
Marijke Braet, S., Jouet, A., Aubry, A., Van Dyck-Lippens, M., Lenoir, E., Assoumani, Y., Baco, A., Mzembaba, A., Cambau, E., Vasconcellos, S. E. G., Rigouts, L., Suffys, P. N., Hasker, E., Supply, P. and de Jong, B. C. (2022). Investigating drug resistance of Mycobacterium leprae in the Comoros: an observational deep-sequencing study. The Lancet Microbe 3, e693–e700, http://doi.org/10.1016/S2666-5247(22)00117-3.
Aubry, A., Sammarco Rosa, P., Chauffour, A., Fletcher, M. L., Cambau, E. and Avanzi, C. (2022). Drug resistance in leprosy: An update following 70years of chemotherapy. Infectious Diseases Now 52, 243–251, http://doi.org/10.1016/j.idnow.2022.04.001.
Chauffour, A., Morel, F., Reibel, F., Petrella, S., Mayer, C., Cambau, E. and Aubry, A. (2021). A systematic review of Mycobacterium leprae DNA gyrase mutations and their impact on fluoroquinolone resistance. Clinical Microbiology and Infection 27, 1601–1612, http://doi.org/10.1016/j.cmi.2021.07.007.
Ortuño-Gutiérrez, N., Mzembaba, A., Ramboarina, S., Andriamira, R., Baco, A., Braet, S., Younoussa, A., Cauchoix, B., Salim, Z., Amidy, M., Grillone, S., Rasamoelina, T., Cambau, E., Geluk, A., de Jong, B. C., Richardus, J. H. and Hasker, E. (2021). Exploring clustering of leprosy in the Comoros and Madagascar: A geospatial analysis. International Journal of Infectious Diseases 108, 96–101, http://doi.org/10.1016/j.ijid.2021.05.014.
Rousset, L., Sokal, A., Vignon-Pennamen, M.-D., Pagis, V., Rybojad, M., Lecorche, E., Mougari, F., Bagot, M., Bouaziz, J.-D. and Jachiet, M. (2020). Association d’une lèpre borderline tuberculoïde et d’une tuberculose : un cas et revue de la littérature. Annales de Dermatologie et de Vénéréologie 147, 886–891, http://doi.org/10.1016/j.annder.2020.09.571.
Avanzi, C., Lécorché, E., Rakotomalala, F. A., Benjak, A., Rapelanoro Rabenja, F., Ramarozatovo, L. S., Cauchoix, B., Rakoto-Andrianarivelo, M., Tió-Coma, M., Leal-Calvo, T., Busso, P., Boy-Röttger, S., Chauffour, A., Rasamoelina, T., Andrianarison, A., Sendrasoa, F., Spencer, J. S., Singh, P., Dashatwar, D. R., Narang, R., Berland, J.-L., Jarlier, V., Salgado, C. G., Moraes, M. O., Geluk, A., Randrianantoandro, A., Cambau, E. and Cole, S. T. (2020). Population Genomics of Mycobacterium leprae Reveals a New Genotype in Madagascar and the Comoros. Frontiers in Microbiology 11, URL: https://www.frontiersin.org/article/10.3389/fmicb.2020.00711 [Accessed March 2022].
Baron, V., Forfait, C., Colot, J., Carzola, C., Descloux, E., Cauchoix, B., Cambau, E., Gaumery, J., Grangeon, J. and Klement, E. (2019). Épidémiologie de la lèpre en Nouvelle-Calédonie de 1983 à 2017. BEH 400–405, URL: https://www.santepubliquefrance.fr/import/epidemiologie-de-la-lepre-en-nouvelle-caledonie-de-1983-a-2017 [Accessed February 2022].
Cambau, E., Saunderson, P., Matsuoka, M., Cole, S. T., Kai, M., Suffys, P., Rosa, P. S., Williams, D., Gupta, U. D., Lavania, M., Cardona-Castro, N., Miyamoto, Y., Hagge, D., Srikantam, A., Hongseng, W., Indropo, A., Vissa, V., Johnson, R. C., Cauchoix, B., Pannikar, V. K., Cooreman, E. a. W. D., Pemmaraju, V. R. R., Gillini, L., Kriswamati, A., Al-Samie, A. R., Issoufou, A., Tiendrebeogo, A., Kingalu, A., Randrianantoandro, A., Kumar, A., Chauffour, A., Win, A. A., Pandey, B., Agrawal, C. M., Widaningrum, C., Schmotzer, C., Kafando, C., Bhandari, C. M., Sema, C., Vidanagama, D. S., Scollard, D. M., Beyene, D., Morelo, E. F., Kassa, E. D., Ramarolahy, E. B., Claco, E., Villalon, E. E., Sidibe, F., Sakho, F., Abdoulaye, F., Guilengue, F. F., Gajete, F., Babu, G. R., Moussa, G., Thakur, G. D., Cabanos, G., Sock, G., Clugston, G., Zaidy, H., Watanabe, H., Kawuma, H. J., Mallari, I. B., Goulart, I. M. B., Ahamed, I., Subbanna, J., Houzeo, J. G., Luengu, J. N. M., Bertolli, J., Lloyd-Owen, J., Matheu, J., Brunelli, J. P., Alzate, J. C. B., Neupane, Kapil Dev, Osuga, K., Yamaguchi, K., Azam, K., Lin, K. M., Momoudu, K., Kyaw, K., Bide, L., Doanh, L. H., My, L. H., Shah, M., Kodio, M., Sidibe, M., Ebenezer, M., Grossi, M. A. de F., Balagon, M. F., Canlonon, M., Makino, M., Htoo, M. M., Ahmed, M. J., Nadine, M.-M., Roferos, F. O., Krismawati, H., Thida, M., Htoon, M. T., Neupane, K. D., Phuc, N. H. N., Van, N. H., Hai, N. P. N., Ishii, N., Soe, O., Amiel, O., Tossou, O., Konare, O., Joshi, P. L., Rao, P. V. R., Krishnamurthy, P., Brennan, P. J., Busso, P., Bhatia, R., Andrianarivelo, M. R., Ramdas, D. R., Chabi, R., Gusmao, R., DjupuriIzwardy, R., Soares, R. C. F. R., Jhadav, R., Buhrer, S., Cho, S.-N. R., Jianping, S., Lzumi, S., Barua, S., Chaitanya, S., Tiendrebeogo, S. M. R., Khang, T. H., Gillis, T. P., Mori, T., Vijayalakshmi, V., Kamara, V. D., Wei, W., Smith, W. C. S., Li, W., Lew, W., Al-Qubati, Y., Suzuki, Y. and Nanba, Y. (2018). Antimicrobial resistance in leprosy: results of the first prospective open survey conducted by a WHO surveillance network for the period 2009–15. Clinical Microbiology and Infection 24, 1305–1310, http://doi.org/10.1016/j.cmi.2018.02.022.
Chauffour, A., Lecorche, E., Reibel, F., Mougari, F., Raskine, L., Aubry, A., Jarlier, V. and Cambau, E. (2018). Prospective study on antimicrobial resistance in leprosy cases diagnosed in France from 2001 to 2015. Clinical Microbiology and Infection 24, 1213.e5-1213.e8, http://doi.org/10.1016/j.cmi.2018.06.004.
Mieras, L. F., Taal, A. T., van Brakel, W. H., Cambau, E., Saunderson, P. R., Smith, W. C. S., Prakoeswa, C. R. S., Astari, L., Scollard, D. M., do Nascimento, D. C., Grosset, J., Kar, H. K., Izumi, S., Gillini, L., Virmond, M. C. L. and Sturkenboom, M. G. G. (2018). An enhanced regimen as post-exposure chemoprophylaxis for leprosy: PEP++. BMC Infectious Diseases 18, 506, http://doi.org/10.1186/s12879-018-3402-4.
Cambau, E. (2018). Antileprosy drugs: mode of action and mechanisms. In: International textbook of leprosy, URL: https://internationaltextbookofleprosy.org/chapter/anti-leprosy-drugs-modes-action-and-mechanisms-resistance-mycobacterium-leprae [Accessed May 2022].
Machado, D., Lecorche, E., Mougari, F., Cambau, E. and Viveiros, M. (2018). Insights on Mycobacterium leprae Efflux Pumps and Their Implications in Drug Resistance and Virulence. Front Microbiol 9, http://doi.org/10.3389/fmicb.2018.03072.
Andre, E., Goeminne, L., Cabibbe, A., Beckert, P., Mukadi, B. K., Mathys, V., Gagneux, S., Niemann, S., Ingen, J. V. and Cambau, E. (2017). Consensus numbering system for the rifampicin resistance-associated rpoB gene mutations in pathogenic mycobacteria. Clinical Microbiology and Infection 23, 167–172, http://doi.org/10.1016/j.cmi.2016.09.006.
Raharolahy, O., Ramarozatovo, L. S., Ranaivo, I. M., Sendrasoa, F. A., Andrianarison, M., Andrianarivelo, M. R., Cambau, E. and Rabenja, F. R. (2016). A Case of Fluoroquinolone-Resistant Leprosy Discovered after 9 Years of Misdiagnosis. Case Reports in Infectious Diseases 2016, 4632369, http://doi.org/10.1155/2016/4632369.
Mieras, L., Anthony, R., van Brakel, W., Bratschi, M. W., van den Broek, J., Cambau, E., Cavaliero, A., Kasang, C., Perera, G., Reichman, L., Richardus, J. H., Saunderson, P., Steinmann, P. and Yew, W. W. (2016). Negligible risk of inducing resistance in Mycobacterium tuberculosis with single-dose rifampicin as post-exposure prophylaxis for leprosy. Infectious Diseases of Poverty 5, 46, http://doi.org/10.1186/s40249-016-0140-y.
Reibel, F., Chauffour, A., Brossier, F., Jarlier, V., Cambau, E. and Aubry, A. (2015). New Insights into the Geographic Distribution of Mycobacterium leprae SNP Genotypes Determined for Isolates from Leprosy Cases Diagnosed in Metropolitan France and French Territories Ed. Johnson, C. PLOS Neglected Tropical Diseases 9, e0004141, http://doi.org/10.1371/journal.pntd.0004141.
Reibel, F., Cambau, E. and Aubry, A. (2015). Update on the epidemiology, diagnosis, and treatment of leprosy. Médecine et Maladies Infectieuses 45, 383–393, http://doi.org/10.1016/j.medmal.2015.09.002.
Reibel, F., Cambau, E. and Aubry, A. (2015). Histoire et actualité du traitement de la lèpre. Journal des Anti-Infectieux 17, 91–98, http://doi.org/10.1016/j.antinf.2015.01.004.
Veziris, N., Chauffour, A., Escolano, S., Henquet, S., Matsuoka, M., Jarlier, V. and Aubry, A. (2013). Resistance of M. leprae to Quinolones: A Question of Relativity? PLoS Negl Trop Dis 7, e2559, http://doi.org/10.1371/journal.pntd.0002559.
Gomez, C., Ponien, P., Serradji, N., Lamouri, A., Pantel, A., Capton, E., Jarlier, V., Anquetin, G. and Aubry, A. (2013). Synthesis of gatifloxacin derivatives and their biological activities against Mycobacterium leprae and Mycobacterium tuberculosis. Bioorganic & Medicinal Chemistry 21, 948–956, http://doi.org/10.1016/j.bmc.2012.12.011.
Cambau, E., Chauffour-Nevejans, A., Tejmar-Kolar, L., Matsuoka, M. and Jarlier, V. (2012). Detection of Antibiotic Resistance in Leprosy Using GenoType LepraeDR, a Novel Ready-To-Use Molecular Test. PLoS Negl Trop Dis 6, e1739, http://doi.org/10.1371/journal.pntd.0001739.
Matrat, S., Cambau, E., Jarlier, V. and Aubry, A. (2008). Are All the DNA Gyrase Mutations Found in Mycobacterium leprae Clinical Strains Involved in Resistance to Fluoroquinolones? Antimicrob Agents Chemother 52, 745–747, http://doi.org/10.1128/AAC.01095-07.
Honoré, N., Roche, P. W., Grosset, J. H. and Cole, S. T. (2001). A method for rapid detection of rifampicin-resistant isolates of Mycobacterium leprae. Lepr Rev 72, 441–448, http://doi.org/10.5935/0305-7518.20010052.
Grosset, J. H. and Cole, S. T. (2001). Genomics and the chemotherapy of leprosy. Lepr Rev 72, 429–440, http://doi.org/10.5935/0305-7518.20010051.
Grosset, J. H. (2001). Newer drugs in leprosy. Int J Lepr Other Mycobact Dis 69, S14-18.
Nguyen, L. N., Cartel, J. L. and Grosset, J. H. (2000). Chemoprophylaxis of leprosy in the southern Marquesas with a single 25 mg/kg dose of rifampicin. Results after 10 years. Lepr Rev 71 Suppl, S33-35; discussion S35-36, http://doi.org/10.5935/0305-7518.20000064.
Ji, B. and Grosset, J. (2000). Combination of rifapentine-moxifloxacin-minocycline (PMM) for the treatment of leprosy. Lepr Rev 71 Suppl, S81-87, http://doi.org/10.5935/0305-7518.20000074.
Consigny, S., Bentoucha, A., Bonnafous, P., Grosset, J. and Ji, B. (2000). Bactericidal activities of HMR 3647, moxifloxacin, and rifapentine against Mycobacterium leprae in mice. Antimicrob Agents Chemother 44, 2919–2921, http://doi.org/10.1128/AAC.44.10.2919-2921.2000.
Ji, B. and Grosset, J. H. (1999). Drugs and regimens for preventive therapy against tuberculosis, disseminated Mycobacterium avium complex infection and leprosy. Int J Lepr Other Mycobact Dis 67, S45-55.
Ji, B., Sow, S., Perani, E., Lienhardt, C., Diderot, V. and Grosset, J. (1998). Bactericidal activity of a single-dose combination of ofloxacin plus minocycline, with or without rifampin, against Mycobacterium leprae in mice and in lepromatous patients. Antimicrob Agents Chemother 42, 1115–1120, http://doi.org/10.1128/AAC.42.5.1115.
Ji, B., Jamet, P., Sow, S., Perani, E. G., Traore, I. and Grosset, J. H. (1997). High relapse rate among lepromatous leprosy patients treated with rifampin plus ofloxacin daily for 4 weeks. Antimicrob Agents Chemother 41, 1953–1956, http://doi.org/10.1128/AAC.41.9.1953.
Mane, I., Cartel, J. L. and Grosset, J. H. (1997). Field trial on efficacy of supervised monthly dose of 600 mg rifampin, 400 mg ofloxacin and 100 mg minocycline for the treatment of leprosy; first results. Int J Lepr Other Mycobact Dis 65, 224–229.
Grosset, J. (1997). Whither short-course chemotherapy for leprosy? Indian J Lepr 69, 119–120.
Ji, B., Levy, L. and Grosset, J. H. (1996). Chemotherapy of leprosy: progress since the Orlando Congress, and prospects for the future. Int J Lepr Other Mycobact Dis 64, S80-88; discussion S88-90.
Ji, B., Jamet, P., Perani, E. G., Sow, S., Lienhardt, C., Petinon, C. and Grosset, J. H. (1996). Bactericidal activity of single dose of clarithromycin plus minocycline, with or without ofloxacin, against Mycobacterium leprae in patients. Antimicrob Agents Chemother 40, 2137–2141, http://doi.org/10.1128/AAC.40.9.2137.
Ji, B., Perani, E. G., Petinom, C. and Grosset, J. H. (1996). Bactericidal activities of combinations of new drugs against Mycobacterium leprae in nude mice. Antimicrob Agents Chemother 40, 393–399, http://doi.org/10.1128/AAC.40.2.393.
Ji, B., Perani, E. G., Petinom, C., N’Deli, L. and Grosset, J. H. (1994). Clinical trial of ofloxacin alone and in combination with dapsone plus clofazimine for treatment of lepromatous leprosy. Antimicrob Agents Chemother 38, 662–667, http://doi.org/10.1128/AAC.38.4.662.
Xiong, J. H., Ji, B., Perani, E. G., Pétinon, C. and Grosset, J. H. (1994). Further study of the effectiveness of single doses of clarithromycin and minocycline against Mycobacterium leprae in mice. Int J Lepr Other Mycobact Dis 62, 37–42.
Honoré, N., Perrani, E., Telenti, A., Grosset, J. and Cole, S. T. (1993). A simple and rapid technique for the detection of rifampin resistance in Mycobacterium leprae. Int J Lepr Other Mycobact Dis 61, 600–604.
Ji, B., Jamet, P., Perani, E. G., Bobin, P. and Grosset, J. H. (1993). Powerful Bactericidal Activities of Clarithromycin and Minocycline against Mycobacterium leprae in Lepromatous Leprosy. J Infect Dis 168, 188–190, http://doi.org/10.1093/infdis/168.1.188.
Ji, B., Perani, E. G., Petinon, C. and Grosset, J. H. (1992). Bactericidal activities of single or multiple doses of various combinations of new antileprosy drugs and/or rifampin against M. leprae in mice. Int J Lepr Other Mycobact Dis 60, 556–561.
Ji, B., Perani, E. G. and Grosset, J. H. (1991). Effectiveness of clarithromycin and minocycline alone and in combination against experimental Mycobacterium leprae infection in mice. Antimicrob Agents Chemother 35, 579–581, http://doi.org/10.1128/AAC.35.3.579.
Ji, B. and Grosset, J. (1991). Ofloxacin for the treatment of leprosy. Acta Leprol 7, 321–326.
Chanteau, S., Cartel, J. L., Perani, E., N’Deli, L., Roux, J. and Grosset, J. H. (1990). Relationships between PGL-1 antigen in serum, tissue and viability of Mycobacterium leprae as determined by mouse footpad assay in multibacillary patients during short-term clinical trial. Lepr Rev 61, 330–340, http://doi.org/10.5935/0305-7518.19900030.
Ji, B. and Grosset, J. H. (1990). Recent advances in the chemotherapy of leprosy. Lepr Rev 61, 313–329, http://doi.org/10.5935/0305-7518.19900029.
Grosset, J. H., Ji, B. H., Guelpa-Lauras, C. C., Perani, E. G. and N’Deli, L. N. (1990). Clinical trial of pefloxacin and ofloxacin in the treatment of lepromatous leprosy. Int J Lepr Other Mycobact Dis 58, 281–295.
N’Deli, L., Guelpa-Lauras, C. C., Perani, E. G. and Grosset, J. H. (1990). Effectiveness of pefloxacin in the treatment of lepromatous leprosy. Int J Lepr Other Mycobact Dis 58, 12–18.
Grosset, J. H., Guelpa-Lauras, C. C., Perani, E. G. and Beoletto, C. (1988). Activity of ofloxacin against Mycobacterium leprae in the mouse. Int J Lepr Other Mycobact Dis 56, 259–264.

Catégories
Documents Tout le CNR-MyRMA

Publications – Buruli

Phillips, R. O., Robert, J., Abass, K. M., Thompson, W., Sarfo, F. S., Wilson, T., Sarpong, G., Gateau, T., Chauty, A., Omollo, R., Ochieng Otieno, M., Egondi, T. W., Ampadu, E. O., Agossadou, D., Marion, E., Ganlonon, L., Wansbrough-Jones, M., Grosset, J., Macdonald, J. M., Treadwell, T., Saunderson, P., Paintsil, A., Lehman, L., Frimpong, M., Sarpong, N. F., Saizonou, R., Tiendrebeogo, A., Ohene, S.-A., Stienstra, Y., Asiedu, K. B., van der Werf, T. S., Osei Mireku, S., Abotsi, J., Adu Poku, J. K., Asamoah-Frimpong, R., Osei-Wusu, B., Sarpong, E., Konadu, B., Opoku, E., Forson, M., Ndogyele, M., Ofori, E., Aboagye, F., Berko, T., Amofa, G., Nsiah, A., Mensah-Bonsu, J., Ofori Nyarko, J., Amoako, Y. A., Koranteng Tannor, E., Boakye-Appiah, J., Dzibordzi Loglo, A., Sarpong-Duah, M., Agbavor, B., Ardent, M. F., Yamadjako, A., Adanmado Gersande, N., Adeye, A., Kindjinou, M., Akpolan, Kiki, M., Sodjinou, E., Guegnard, C., Klis, S.-A., Velding, K., Omansen, T., Ofori-Adjei, D., Eyangoh, S., Knell, A. and Faber, W. (2020). Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-inferiority phase 3 trial. The Lancet 395, 1259–1267, http://doi.org/10.1016/S0140-6736(20)30047-7.
Chauffour, A., Robert, J., Veziris, N., Aubry, A., Pethe, K. and Jarlier, V. (2020). Telacebec (Q203)-containing intermittent oral regimens sterilized mice infected with Mycobacterium ulcerans after only 16 doses. PLOS Neglected Tropical Diseases 14, e0007857, http://doi.org/10.1371/journal.pntd.0007857.
Scherr, N., Bieri, R., Thomas, S. S., Chauffour, A., Kalia, N. P., Schneide, P., Ruf, M.-T., Lamelas, A., Manimekalai, M. S. S., Grüber, G., Ishii, N., Suzuki, K., Tanner, M., Moraski, G. C., Miller, M. J., Witschel, M., Jarlier, V., Pluschke, G. and Pethe, K. (2018). Targeting the Mycobacterium ulcerans cytochrome bc 1 : aa 3 for the treatment of Buruli ulcer. Nature Communications 9, 5370, http://doi.org/10.1038/s41467-018-07804-8.
Chauffour, A., Robert, J., Veziris, N., Aubry, A. and Jarlier, V. (2016). Sterilizing Activity of Fully Oral Intermittent Regimens against Mycobacterium ulcerans Infection in Mice. PLOS Neglected Tropical Diseases 10, e0005066, http://doi.org/10.1371/journal.pntd.0005066.
Ruf, M.-T., Schütte, D., Chauffour, A., Jarlier, V., Ji, B. and Pluschke, G. (2012). Chemotherapy-Associated Changes of Histopathological Features of Mycobacterium ulcerans Lesions in a Buruli Ulcer Mouse Model. Antimicrob Agents Chemother 56, 687–696, http://doi.org/10.1128/AAC.05543-11.
Marsollier, L., Aubry, A., Carbonnelle, E., Canaan, S., Cambau, E. and Herrmann, J.-L. (2010). Les Mycobactérioses cutanées dues à Mycobacterium ulcerans, Mycobacterium marinum, Mycobacterium abscessus, Mycobacterium chelonae et autres mycobactéries non tuberculeuses, L’Encyclopédie Médico-chirurgicale.
Ji, B., Chauffour, A., Aubry, A., Robert, J., Ibrahim, M. and Jarlier, V. (2009). Impacts of Dosing Frequency of the Combination Rifampin-Streptomycin on Its Bactericidal and Sterilizing Activities against Mycobacterium ulcerans in Mice. Antimicrob Agents Chemother 53, 2955–2959, http://doi.org/10.1128/AAC.00011-09.
Ji, B., Chauffour, A., Robert, J. and Jarlier, V. (2008). Bactericidal and Sterilizing Activities of Several Orally Administered Combined Regimens against Mycobacterium ulcerans in Mice. Antimicrob Agents Chemother 52, 1912–1916, http://doi.org/10.1128/AAC.00193-08.
Ji, B., Chauffour, A., Robert, J., Lefrançois, S. and Jarlier, V. (2007). Orally Administered Combined Regimens for Treatment of Mycobacterium ulcerans Infection in Mice. Antimicrob Agents Chemother 51, 3737–3739, http://doi.org/10.1128/AAC.00730-07.
Lefrançois, S., Robert, J., Chauffour, A., Ji, B. and Jarlier, V. (2007). Curing Mycobacterium ulcerans Infection in Mice with a Combination of Rifampin-Streptomycin or Rifampin-Amikacin. Antimicrob Agents Chemother 51, 645–650, http://doi.org/10.1128/AAC.00821-06.
Ji, B., Lefrançois, S., Robert, J., Chauffour, A., Truffot, C. and Jarlier, V. (2006). In Vitro and In Vivo Activities of Rifampin, Streptomycin, Amikacin, Moxifloxacin, R207910, Linezolid, and PA-824 against Mycobacterium ulcerans. Antimicrob Agents Chemother 50, 1921–1926, http://doi.org/10.1128/AAC.00052-06.
Dega, H., Bentoucha, A., Robert, J., Jarlier, V. and Grosset, J. (2002). Bactericidal Activity of Rifampin-Amikacin against Mycobacterium ulcerans in Mice. Antimicrob Agents Chemother 46, 3193–3196, http://doi.org/10.1128/AAC.46.10.3193-3196.2002.
Bentoucha, A., Robert, J., Dega, H., Lounis, N., Jarlier, V. and Grosset, J. (2001). Activities of New Macrolides and Fluoroquinolones against Mycobacterium ulcerans Infection in Mice. Antimicrob Agents Chemother 45, 3109–3112, http://doi.org/10.1128/AAC.45.11.3109-3112.2001.
Dega, H., Robert, J., Bonnafous, P., Jarlier, V. and Grosset, J. (2000). Activities of Several Antimicrobials againstMycobacterium ulcerans Infection in Mice. Antimicrob Agents Chemother 44, 2367–2372, http://doi.org/10.1128/AAC.44.9.2367-2372.2000.